iX Biopharma: Reports Positive Results From Pharmacokinetic Study Of BnoX.

15 May 2017 - ShareInvestor Express
iX Biopharma Ltd. is pleased to announce the results of BUP001, a pharmacokinetic study of its novel sublingual buprenorphine wafer, BnoX. BnoX, which uses the Group's patented sublingual drug delivery technology, WaferiX, is one of the Group's products under development for pain management...
sgx:42c

---

iX Biopharma: Prepares For WafeRest Launch.

12 May 2017 - ShareInvestor Express
Filed for registration of PheoniX with TGA in April 2017. Completed pharmacokinetic study of BnoX...
sgx:42c

---

iX Biopharma: Secures South African Patent For WaferiX Drug Delivery Technology.

21 Nov 2016 - ShareInvestor Express
iX Biopharma Ltd. has been granted a patent in South Africa (no. 2014/00310) for its WaferiX drug delivery technology. The patent will expire on 26 October 2030...
sgx:42c

---

iX Biopharma: Reports Good Progress On Drug Development In 1Q17.

14 Nov 2016 - ShareInvestor Express
iX Biopharma Ltd. made significant progress in its product pipeline and cost management during the financial quarter ended 30 September 2016...
sgx:42c

---

iX Biopharma: Secures Canadian Patent For WaferiX Drug Delivery Technology.

1 Nov 2016 - ShareInvestor Express
iX Biopharma Ltd. has been granted a patent in Canada (no. 2777218) for its WaferiX drug delivery technology. Canada has a potential market size of C$515 million and C$97 million for opioids and sleep aids, according to Patented Medicine Prices Review Board of Canada and Euromonitor respectively...
sgx:42c

---

Stocks to watch: Imperium Crown, Rickmers Maritime Trust, Ley Choon Group, iX Biopharma

1 Nov 2016 - Business Times Breaking News
THE following companies made announcements after Monday's market close that could affect their shares trading when the market opens on Tuesday: Property investment firm Imperium Crown is planning to invest S$5 million in two cineplexes in China, which it says will open opportunities for the group to ...
sgx:5ht sgx:42c sgx:b1zu sgx:q0x

---

iX Biopharma granted patent in Canada for WaferiX

31 Oct 2016 - Business Times Breaking News
HOMEGROWN specialty pharmaceutical company iX Biopharma has been granted a patent in Canada for its WaferiX drug delivery technology. The grant of the Canadian patent expires on Oct 26, 2030.
sgx:42c

---

iX Biopharma: Announces Positive Results From Pivotal Study Of Erectile Dysfunction Drug.

13 Sep 2016 - ShareInvestor Express
Results of pivotal study confirm bioequivalence and good oral tolerability of sublingual sildenafil wafer (PheoniX) when compared with reference drug...
sgx:42c

---

iX Biopharma IPO draws strong response

22 Jul 2015 - DealStreetAsia
Posted July 22nd, 2015 by Team DealStreetAsia ( [email protected]) & filed under IPOs Late-stage specialty pharmaceutical company iX Biopharma Ltd’s initial public offering (IPO) has seen a strong response from institutional and retail investors for its initial public offering. The company’s ...
sgx:42c

---

iX Biopharma IPO: Interesting product, uncertain outlook

17 Jul 2015 - DealStreetAsia
Late-stage specialty pharmaceutical firm iX Biopharma Ltd. (iX Biopharma), which has its roots in Australia, is launching its initial public offering (IPO), in conjunction with a proposed listing on Catalist, the sponsor-supervised listing board of the Singapore Exchange (SGX). CIMB Bank (Singapore) ...
sgx:42c

---